Summary
This clinical trial for patients with HER2-positive endometrial cancer. Cancer cells that are making too many copies of a certain protein are called HER2. This trial is testing if adding one of two HER2-targeted drug combinations to standard chemotherapy can improve outcomes for patients with HER2-positive endometrial serous carcinoma or carcinosarcoma. Participants are assigned to one of three groups: Group 1: Standard treatment with paclitaxel and carboplatin. Group 2: Standard chemotherapy plus Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk). Group 3: Standard chemotherapy plus Phesgo™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf).
Description
Eligibility highlights
Condition: Participants must have HER2-positive endometrial serous carcinoma or carcinosarcoma that is stage I-IV.
Status: Patients cannot have a recurrent disease and must not have received prior chemotherapy.
Age: Adults 18 years and older.
Gender: Female